Myre is a medical oncologist with Elmhurst Hematology Oncology Group in Elmhurst, Illinois.
Letter: Declassifying Gleason 6 as a cancer would do more harm than good
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
FDA grants breakthrough device designation for ArteraAI Prostate tool
Data supports combination intravesical chemotherapy for high-risk NMIBC
EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC
FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC